RNAi therapeutics: principles, prospects and challenges.
about
RNAi and RNAa--the yin and yang of RNAomeRibonucleases as novel chemotherapeutics : the ranpirnase exampleMicroRNAs: Novel immunotherapeutic targets in colorectal carcinomaRNA interference therapy: a new solution for intracranial atherosclerosis?MicroRNAs in heart failure: Small molecules with major impactHarnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinomaDelivery of RNAi Therapeutics to the Airways-From Bench to BedsideRecent advances in dendrimer-based nanovectors for tumor-targeted drug and gene deliveryAdvances in PEGylation of important biotech molecules: delivery aspectsTranslational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory DiseasesCofilin activation mediates Bax translocation to mitochondria during excitotoxic neuronal deathKnocking down HMGB1 using dendrimer-delivered siRNA unveils its key role in NMDA-induced autophagy in rat cortical neuronssiRNA off-target effects can be reduced at concentrations that match their individual potencyPigmy MicroRNA: surveillance cops in Therapies kingdomMicrornas in prostate cancer: an overview.Improved knockdown from artificial microRNAs in an enhanced miR-155 backbone: a designer's guide to potent multi-target RNAiPhospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo.Trends in the Binding of Cell Penetrating Peptides to siRNA: A Molecular Docking Study.The trypanosome transcriptome is remodelled during differentiation but displays limited responsiveness within life stages.Acetylation of PAMAM dendrimers for cellular delivery of siRNA.Targeted suppression of heme oxygenase-1 by small interference RNAs inhibits the production of bilirubin in neonatal rat with hyperbilirubinemia.SiRNA Delivery with PEGylated Graphene Oxide Nanosheets for Combined Photothermal and Genetherapy for Pancreatic Cancer.Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cellsRNA interference in schistosomes: machinery and methodologyA new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells.Cell- and region-specific miR30-based gene knock-down with temporal control in the rat brainEffect of small interfering RNAs on matrix metalloproteinase 1 expression.Modeling RNA interference in mammalian cellsTransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery.Update on current and potential nanoparticle cancer therapiesCationic amphiphilic macromolecule (CAM)-lipid complexes for efficient siRNA gene silencing.Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.Tailoring the RNAi efficiency of polyplexes.siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption.A Salmonella Typhimurium mutant strain capable of RNAi delivery: higher tumor-targeting and lower toxicity.Targeted gene silencing using RGD-labeled chitosan nanoparticles.PEG-detachable cationic polyaspartamide derivatives bearing stearoyl moieties for systemic siRNA delivery toward subcutaneous BxPC3 pancreatic tumor.Targeting microRNAs in cancer: rationale, strategies and challenges.Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors
P2860
Q24642007-0E5E6F70-9653-4860-81F5-5DF0976642A0Q24650138-B77AC05E-901B-4BC1-B05B-A5ACB7F760DCQ26747339-134051E9-E57C-436C-8304-3FFBF093452AQ26860451-8A3E844E-7F4A-47FE-A691-74912646050BQ27024714-6ED51103-D5BA-4D90-86CB-689AF7A15D58Q27488744-E979E726-AEF6-4D87-B88C-CE891681F0B3Q28067306-9456733D-5C8C-4884-A5F9-7072582353D0Q28085438-130C1A0C-75D4-49C2-997A-7B6DC8B39810Q28277255-145CFA82-8C5D-4778-A560-B311F0DD32BCQ28548580-73F5D149-8168-44EF-9915-48BDD79ADF19Q28572415-D1E9A998-5874-42B3-8088-430985E8E4F8Q28575459-B4051854-8019-415D-B76D-CAB965F76FE3Q28742959-240E1E8B-92CD-4D8E-A7BA-DA79BF601A1AQ28818470-B8D4985E-8503-4028-9588-D2482F7DC919Q30234658-F173F3AF-690B-4AB4-AF9D-9557348F5303Q30388048-661DC408-1BD0-43CC-BFF5-841214B93C8AQ30403731-29EA1C3D-DE8F-4792-909A-7C6367ED78B0Q30475089-7229D481-61C3-42D2-BC76-E3D31AB42C49Q30840924-F7127EEA-1AB9-43FA-8EE0-F941F9D5D661Q33345915-61CE907D-7EF3-476C-B9CE-D41EF046EE14Q33434160-216951E8-BF77-4A48-BD52-BB019B594AE9Q33489075-DDAEFC4E-767B-4317-93F2-AEA1784DC92DQ33588169-CB5561E4-9219-4359-AE0D-568505EAD922Q33593020-9AEC70B6-9DCF-4FB1-87CE-FADA69942983Q33695469-A415BFEB-113B-4905-944E-17233D968668Q33712960-1B36B3F2-BCC3-4801-B735-089A67A5625EQ33763933-1B753C42-494B-47A6-8FF6-F8722D5D7621Q33783170-767F491C-8AED-4252-9FBA-E9C6B57D9B9DQ33805528-892F994D-FB60-4D1A-A814-1E21C2318DDAQ33848915-B4A4E9ED-6408-4F15-B4AD-82B6410A23A2Q33874239-45105BEB-AE6F-4378-A226-FA6B5330A697Q33875414-D79F5F0B-67ED-428C-A872-55ECE97C2C63Q33893647-F7F4C939-DF08-473B-B6DA-7EBEA97B0E11Q33911262-6E65425A-E2DF-44EF-B069-EA39FE0DEC31Q33912421-8C0EA0B4-06B8-4DE3-A126-1A5DE0B15B99Q33989955-29F966FB-71E1-4869-B92E-398C1FD68374Q34031859-BB47272E-8EBC-4991-A729-91A961B99A0FQ34069847-6F0B18AF-82CB-44FF-B118-125295922170Q34141089-CDEF7317-E5B5-4BFF-8C22-4BAA2E966C6CQ34165321-F730E45B-A786-4C19-B243-0FA80A254FC8
P2860
RNAi therapeutics: principles, prospects and challenges.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
RNAi therapeutics: principles, prospects and challenges.
@ast
RNAi therapeutics: principles, prospects and challenges.
@en
RNAi therapeutics: principles, prospects and challenges.
@nl
type
label
RNAi therapeutics: principles, prospects and challenges.
@ast
RNAi therapeutics: principles, prospects and challenges.
@en
RNAi therapeutics: principles, prospects and challenges.
@nl
prefLabel
RNAi therapeutics: principles, prospects and challenges.
@ast
RNAi therapeutics: principles, prospects and challenges.
@en
RNAi therapeutics: principles, prospects and challenges.
@nl
P2860
P1476
RNAi therapeutics: principles, prospects and challenges.
@en
P2093
John J Rossi
Lars Aagaard
P2860
P356
10.1016/J.ADDR.2007.03.005
P407
P577
2007-03-16T00:00:00Z